Lang
The global market for fish oil concentration and refinement is projected to experience substantial growth, reaching an estimated $5 billion by 2035. This expansion follows a valuation of $2.6 billion in 2025, with the market expected to grow from $2.7 billion in 2026 at a robust compound annual growth rate (CAGR) of 6.8% between 2026 and 2035. These figures are based on the latest report published by Global Market Insights Inc.
Several factors are propelling this market forward, including the increasing demand for cardiovascular and cognitive health supplements, the expanding pipeline of prescription omega-3 pharmaceuticals, and the growth of the aquaculture sector. Opportunities for further expansion lie in the pharmaceutical active pharmaceutical ingredient (API) market beyond hypertriglyceridemia and the differentiation offered by green concentration technologies. However, the industry faces challenges such as volatile anchovy catch quotas, potential supply disruptions from El Niño events, and the significant cost burden associated with dual pharmacopeial certifications.
A significant commercial shift is underway with a migration from commodity ethyl ester (EE) concentrates to re-esterified triglyceride (rTG) forms. This transition is driven by a growing body of clinical evidence, including comparative bioavailability studies, demonstrating that rTG concentrates offer 25–50% greater plasma EPA and DHA area-under-the-curve compared to equivalent doses of EE. This pharmacokinetic advantage is increasingly leveraged in premium supplement brand positioning and contract specifications. A Q3 2025 survey of 210 dietary supplement brand managers across North America, Europe, and APAC revealed that 58% had either completed or initiated a reformulation from EE to rTG in the prior 24 months, with 71% of those yet to transition citing cost differential as the primary barrier. The rTG segment, holding approximately 20% value share in 2025, is expanding at an impressive ~9.5% CAGR through 2035, which is about 1.4 times the overall market rate. Premium rTG products, with over 90% triglyceride purity, are growing even faster at an ~11% CAGR. This medium-to-long-term structural shift (2–7 years) is being propelled by both consumer education at the brand level and tightening procurement specifications from manufacturers. Leading product lines anchoring premium supply include Croda International's Incromega™ rTG series and Epax Norway AS's rTG portfolio, which features formulations like the Epax 6000TG balanced EPA/DHA.
In response to escalating regulatory and sustainability pressures, solvent-free processing technologies are gaining commercial traction. Membrane-based filtration and supercritical fluid extraction (SFE) are moving from pilot-scale demonstration to commercial integration. This shift is influenced by the European Food Safety Authority's (EFSA) ongoing assessment of mineral oil aromatic hydrocarbon (MOAH) contamination limits in edible fats, which disadvantages hexane-dependent molecular distillation, and the increasing demand from premium supplement brands for solvent-free procurement. Membrane-based filtration is the fastest-growing technology segment, projected at a ~12.5% CAGR, advancing from approximately 3% market share in 2025 as processors seek intermediate concentration stages that completely avoid solvent contact. OLVEA Fish Oils in Fécamp, France, has incorporated membrane-assisted deacidification, while GC Rieber VivoMega AS in Bergen, Norway, utilizes membrane separation for intermediate concentration steps. SFE, with an ~7% share and ~8.8% CAGR, offers the highest-specification solvent-free output, although it requires a materially higher capital investment than membrane systems, making it the preferred route for pharmaceutical-grade API production where absolute solvent-residue traceability is critical. The commercial inflection point for this trend is anticipated in the medium term (2–5 years) as EFSA's MOAH regulatory framework progresses towards enforceable limits and sustainability-credentialed procurement practices extend globally.
In terms of concentration and refinement technology, molecular distillation dominated the market in 2025 with an approximate 48% revenue share and is expected to grow at a ~6.2% CAGR through 2035. Other technologies include enzymatic processing, urea complexation, supercritical fluid extraction, membrane-based filtration, winterization & fractional crystallization, and others. Regarding output product form, ethyl ester (EE) held the largest market share at approximately 42% in 2025, alongside re-esterified triglyceride (rTG), natural triglyceride (TG), phospholipid, and free fatty acid (FFA). By source species, anchovy/anchoveta dominated in 2025, accounting for approximately 40% of revenue share and growing at a ~6.5% CAGR through 2035. Other significant source species include salmon & salmonids, sardine/pilchard, mackerel, herring, and tuna.
Regionally, Europe emerged as the largest market in 2025, holding approximately 31% of the global fish oil concentration and refinement market share and projected to grow at a ~5.8% CAGR through 2035. Asia Pacific represented approximately 28% of the market in 2025 but is anticipated to be the fastest-growing region, with an impressive ~8.1% CAGR, leading to a significantly expanded revenue share by 2035. North America contributed approximately 22% to the market in 2025. Latin America is also set for significant expansion between 2026 and 2035, with Peru and Chile positioned as dominant processors. The Middle East & Africa region is expected to demonstrate the second-fastest regional growth rate, expanding at an approximate 7.8% CAGR between 2026 and 2035.
The fish oil concentration and refinement industry is moderately consolidated, with the top five players—BASF SE (Pronova), dsm-firmenich, Epax Norway AS, KD Pharma Group SA, and Golden Omega—collectively holding approximately 45–50% of the total market share in 2025. These leading companies operate across pharmaceutical-grade, premium nutraceutical, and commodity-grade concentration tiers, primarily differentiated by their pharmacopeial certification scope, proprietary enzymatic re-esterification intellectual property (IP), and certified feedstock procurement infrastructure. Industry experts suggest that the next five years will be defined less by volume competition at the commodity tier and more by certification breadth and speed-to-specification, specifically the ability to rapidly develop and validate new omega-3 output forms against pharmaceutical partner API requirements. The May 2023 merger of Royal DSM and Firmenich, forming dsm-firmenich, created a robust nutrition and health platform with substantial omega-3 concentration capabilities and cross-sell infrastructure, marking a significant competitive reshaping event. Further M&A consolidation is expected, driven by the scale incentives created by pharmaceutical-grade certification requirements.
BASF SE, through its Pronova subsidiary in Ålesund, Norway, stands as the global market leader in pharmaceutical-grade omega-3 API production. Its PronovaPure™ franchise includes EPA and DHA concentrates manufactured to USP 40 and Ph.Eur. 10.0 specifications, supported by active FDA Drug Master Files and European Pharmacopoeia CEP designations. BASF's strength lies in its comprehensive certification scope, advanced contamination testing infrastructure, and long-term procurement relationships for pharmaceutical-grade crude fish oil feedstock that meets stringent PCB, dioxin, and MOAH contamination limits. dsm-firmenich, formed by the May 2023 merger of Royal DSM and Firmenich, combines DSM's OMEGATEX® omega-3 nutrition product line with Firmenich's expertise in flavor, encapsulation, and functional ingredients. This merged entity operates omega-3 concentration assets across Europe and possesses the commercial infrastructure to serve global supplement and food fortification customers, with cross-sell capabilities between omega-3 ingredient supply and encapsulation or flavoring solutions. Epax Norway AS, based in Ålesund, Norway, is a highly specialized omega-3 refiner focusing on high-purity EE and rTG concentrates for pharmaceutical and premium nutraceutical applications. Epax's proprietary enzymatic re-esterification process for rTG production is well-established, with its pharmaceutical-grade Epax 500E (EPA) and Epax 6000TG (balanced EPA/DHA rTG) portfolio distributed under long-term supply agreements. KD Pharma Group SA, operating from Bexbach, Germany, specializes exclusively in omega-3 fatty acid concentration and pharmaceutical-grade API production. Holding EU GMP certification and active CEP designations, and serving as a US FDA Drug Master File holder, KD Pharma's dedicated focus provides a depth of process expertise and regulatory documentation capability that distinguishes it from generalist competitors.
In March 2025, KD Pharma Group SA announced the completion of a capacity expansion at its Bexbach, Germany facility, boosting its omega-3 pharmaceutical-grade API output by approximately 25%. These expanded production lines have been validated under EU GMP and cleared for Drug Master File updates with the FDA. Separately, in January 2025, Golden Omega secured a long-term certified crude fish oil supply agreement with TASA (Tecnológica de Alimentos S.A.) in Peru. This agreement aims to ensure multi-year feedstock security in anticipation of forecast anchovy quota volatility linked to residual ENSO uncertainty in the South Pacific.
Source: Global Market Insights Inc.